Company Overview and News

0
Heineken, China Resources Beer seal US$3.1 billion tie-up in premium brands push

2018-08-03 channelnewsasia
Heineken said it signed a non-binding agreement with China Resources Enterprise Limited and China Resources Beer Holdings and will become a minority partner with a 40 percent stake in the holding company CRH (Beer) Limited.
0291 ABI HEIA

0
Heineken agrees to sell China operation to CR Beer in $3.1 bln deal

2018-08-03 theedgemarkets
HONG KONG (Aug 3): Heineken NV said on Friday it has agreed to sell its China operations and take a 40 percent stake in a firm controlling the country's biggest beer maker China Resources Beer Co Ltd in a $3.1 billion deal.
0291 ABI HEIA

0
Heineken enters deal with China Resources Enterprise and China Resources Beer

2018-08-03 reuters
(Reuters) - Heineken said it signed a non-binding agreement with China Resources Enterprise Limited and China Resources Beer Holdings and will become a minority partner with a 40 percent stake in the holding company CRH (Beer) Limited.
0291

0
Heineken enters deal with China Resources Enterprise and China Resources Beer

2018-08-03 channelnewsasia
Heineken said it signed a non-binding agreement with China Resources Enterprise Limited and China Resources Beer Holdings and will become a minority partner with a 40 percent stake in the holding company CRH (Beer) Limited.
0291

0
HEINEKEN and China Resources sign non-binding agreements to join forces in China

2018-08-02 globenewswire
Amsterdam, 3 August 2018 - Heineken N.V. ('HEINEKEN') (EURONEXT: HEIA; OTCQX: HEINY) today announced that it has signed non-binding agreements with China Resources Enterprise, Limited ('CRE') and China Resources Beer (Holdings) Co. Ltd. ('CR Beer') to create a long-term strategic partnership for Mainland China, Hong Kong and Macau (together 'China'). In the context of this partnership, HEINEKEN will become CRE's 40% minority partner in holding company CRH (Beer) Limited ('CBL'), which controls CR Beer, the undisputed market leader in the world's largest beer market, China.
0291

Related Articles

REPH: Recro Pharma Analysis and Research Report

1h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

1h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2h - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...